Indirect Effexor Buyers Seek Approval Of $2.3M Antitrust Deal
A proposed class of indirect drug purchasers have asked a New Jersey federal judge for his initial sign-off on a $2.25 million deal with Teva Pharmaceuticals to resolve antitrust claims against...To view the full article, register now.
Already a subscriber? Click here to view full article